The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where François Gros sits on this spectrum.
This scientist: 260 publications — 70th percentile
70% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 1,028 publications or more.
The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where François Gros sits on this spectrum.
This scientist: 66 D-Index — 57th percentile
57% of scientists in this discipline score the same or lower.
The last bar groups every scientist with 167 D-Index or more.
François Gros is affiliated with the Collège de France in France and has contributed extensively to the field of medicine, with a specialized focus on oncology and related biomedical disciplines. Their research portfolio spans topics such as CAR-T cell therapy research, lymphoma diagnosis and treatment, biosimilars and bioanalytical methods, viral infectious diseases and gene expression in insects, chronic lymphocytic leukemia research, acute lymphoblastic leukemia research, and lung cancer treatments and mutations.
Within these areas, they have explored numerous subfields including oncology, immunology, molecular biology, pathology and forensic medicine, and genetics. Their publication record reflects a concentration on hematological cancers and immunotherapy approaches, as evidenced by a number of papers published in highly recognized scientific venues.
Recent papers authored by François Gros include the following:
Some of the frequent publication venues for François Gros include:
They have collaborated frequently with a number of co-authors, highlighting a network engaged in lymphoma and hematology research. Notable frequent coauthors include:
François Gros's work demonstrates a sustained interest in advancing therapeutic protocols for hematological malignancies, with particular attention to the clinical outcomes of CAR-T cell therapies and immunotherapeutic combinations. Their contributions extend across clinical investigations and translational research aimed at improving intervention strategies for lymphomas and related hematological disorders.
Francois Gros;H. Hiatt;Walter Gilbert;C. G. Kurland
B Edde;J Rossier;JP Le Caer;E Desbruyeres
A J Minty;M Caravatti;B Robert;A Cohen
Josette Rouviere-Yaniv;Francois Gros
Robert G. Whalen;Gillian S. Butler-Browne;François Gros
M Escurat;K Djabali;M Gumpel;F Gros
R G Whalen;G S Butler-Browne;F Gros
A Wolff;B de Néchaud;D Chillet;H Mazarguil
Dominique Boucher;Jean-Christophe Larcher;Francois Gros;Philippe Denoulet
Robert G. Whalen;Ketty Schwartz;Pierre Bouveret;Susan M. Sell
Jean-Christophe Larcher;Dominique Boucher;Sylvie Lazereg;François Gros
Klaus Scherrer;Lise Marcaud;Francois Zajdela;Irving M. London
S Gautron;G Dos Santos;D Pinto-Henrique;A Koulakoff
Roger Monier;Shiro Naono;Donal Hayes;Françoise Hayes
M. E. Buckingham;D. Caput;A. Cohen;R. G. Whalen
M. Revel;M. Herzberg;A. Becarevic;F. Gros
M. Revel;J. C. Lelong;G. Brawerman;F. Gros
D Montarras;M Y Fiszman;F Gros
S Audebert;E Desbruyères;C Gruszczynski;A Koulakoff
François Gros;Walter Gilbert;Howard H. Hiatt;G. Attardi
If you think any of the details on this page are incorrect, let us know.
